Clinical outcome at 5 years for 186 patients randomized to receive or not receive an autologous stem cell transplant
. | FLT3/ITD- . | . | . | FLT3/ITD+ . | . | . | Overall . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | SCT . | No SCT . | OR (95% CI) . | SCT . | No SCT . | OR (95% CI) . | OR (95% CI) . | Het P* . | |||||
| Patients | 68 | 57 | — | 35 | 26 | — | — | — | |||||
| TRM | 27% | 4% | 6.99 (1.16-4.21) | 19% | 18% | 0.99 (0.35-2.80) | 1.62 (0.66-3.99) | .06 | |||||
| RR | 40% | 50% | 0.69 (0.40-1.18) | 59% | 89% | 0.41 (0.21-0.80) | 0.56 (0.37-0.86) | .2 | |||||
| DFS | 49% | 48% | 0.96 (0.59-1.55) | 33% | 8% | 0.45 (0.25-0.83) | 0.72 (0.49-1.05) | .06 | |||||
| OS | 55% | 57% | 1.05 (0.64-1.73) | 48% | 8% | 0.40 (0.21-0.76) | 0.73 (0.49-1.08) | .02 | |||||
. | FLT3/ITD- . | . | . | FLT3/ITD+ . | . | . | Overall . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | SCT . | No SCT . | OR (95% CI) . | SCT . | No SCT . | OR (95% CI) . | OR (95% CI) . | Het P* . | |||||
| Patients | 68 | 57 | — | 35 | 26 | — | — | — | |||||
| TRM | 27% | 4% | 6.99 (1.16-4.21) | 19% | 18% | 0.99 (0.35-2.80) | 1.62 (0.66-3.99) | .06 | |||||
| RR | 40% | 50% | 0.69 (0.40-1.18) | 59% | 89% | 0.41 (0.21-0.80) | 0.56 (0.37-0.86) | .2 | |||||
| DFS | 49% | 48% | 0.96 (0.59-1.55) | 33% | 8% | 0.45 (0.25-0.83) | 0.72 (0.49-1.05) | .06 | |||||
| OS | 55% | 57% | 1.05 (0.64-1.73) | 48% | 8% | 0.40 (0.21-0.76) | 0.73 (0.49-1.08) | .02 | |||||
OR indicates odds ratio; CI, confidence interval; TRM, treatment-related mortality; RR, relapse risk, DFS, disease-free survival; OS, overall survival; and —, not applicable.
Heterogeneity P values (Het P) are for the interaction between transplant or no transplant and FLT3/ITD status